Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marzieh K. Atigh"'
Autor:
Marzieh K. Atigh, Emily Goel, Megan Erwin, Ricky Greer, Jacques Ohayon, Roderic I. Pettigrew, Saami K. Yazdani
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Perfusion catheters have recently emerged as a novel approach to deliver liquid anti-proliferative agents into flow obstructed arterial segments. The purpose of this study was to determine the impact of luminal delivery pressure on liquid dr
Externí odkaz:
https://doaj.org/article/4dc75708f326434e88b03657883d5e7b
Autor:
Emily Goel, Marzieh K. Atigh, Saami K. Yazdani, Roderic I. Pettigrew, Megan Erwin, Jacques Ohayon, Ricky Greer
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Perfusion catheters have recently emerged as a novel approach to deliver liquid anti-proliferative agents into flow obstructed arterial segments. The purpose of this study was to determine the impact of luminal delivery pressure on liquid drug penetr
Autor:
Saami K. Yazdani, Emily Goel, Uwe Christians, Claire V. Cawthon, Marzieh K. Atigh, Kathryn Cooper
Publikováno v:
Frontiers in Medical Technology, Vol 3 (2021)
Frontiers in Medical Technology
Frontiers in Medical Technology
Purpose: The goal of this study was to develop an ex vivo system capable of rapidly evaluating arterial drug levels in living, isolated porcine carotid arteries.Methods: A vascular bioreactor system was developed that housed a native porcine carotid
Autor:
Saami K. Yazdani, Megan Erwin, Uwe Christians, Emily Turner, Marzieh K. Atigh, Justin M. Saul
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 9 (2018)
Frontiers in Pharmacology, Vol 9 (2018)
Purpose: Drug coated balloons (DCB) are continually improving due to advances in coating techniques and more effective excipients. Paclitaxel, the current drug choice of DCB, is a microtubule-stabilizing chemotherapeutic agent that inhibits smooth mu
Publikováno v:
Cardiovascular engineering and technology. 9(2)
PURPOSE: Drug coated balloons (DCB) are becoming the standard-care treatment for peripheral arterial disease (PAD). DCB use excipients to transfer and retain anti-proliferative drugs, such as paclitaxel. Excipients thus play a vital role in the desig
Aim Non-stent drug delivery platforms have recently emerged as an alternative treatment of peripheral arterial disease. Perfusion catheters have the potential to directly deliver anti-proliferative agents to the medial arterial layer to prevent reste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e447a0b8a4106fe977a2896ff3e1fc73
https://europepmc.org/articles/PMC5511576/
https://europepmc.org/articles/PMC5511576/
Autor:
Marzieh K. Atigh, Saami K. Yazdani
Publikováno v:
2016 32nd Southern Biomedical Engineering Conference (SBEC).
Peripheral Artery Disease (PAD) is one of the major causes of morbidity that affects approximately 10 million people in the US. PAD is caused by atherosclerosis, which causes hardening and narrowing of the artery. It is hypothesized that, PAD reduces